Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases

[1]  M. Vogel,et al.  Allergens displayed on virus‐like particles are highly immunogenic but fail to activate human mast cells , 2018, Allergy.

[2]  R. Janssen,et al.  Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. , 2018, Vaccine.

[3]  D. Stuart,et al.  Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy , 2017, npj Vaccines.

[4]  M. Bachmann,et al.  Major findings and recent advances in virus-like particle (VLP)-based vaccines. , 2017, Seminars in immunology.

[5]  M. Bachmann,et al.  Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax , 2017, Vaccines.

[6]  T. Kündig,et al.  Allergen‐specific immunotherapy: is it vaccination against toxins after all? , 2017, Allergy.

[7]  I. Pali-Schöll,et al.  The concept of allergen-associated molecular patterns (AAMP). , 2016, Current opinion in immunology.

[8]  C. Stremnitzer,et al.  Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform , 2016, Oncoimmunology.

[9]  C. Stremnitzer,et al.  Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice. , 2014, Viral immunology.

[10]  L. Klimek,et al.  Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs , 2013, American journal of rhinology & allergy.

[11]  W. Renner,et al.  The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. , 2013, The Journal of allergy and clinical immunology.

[12]  R. Schlosser,et al.  Subcutaneous and sublingual immunotherapy for allergic rhinitis: What is the evidence? , 2012, American journal of rhinology & allergy.

[13]  O. Pfaar,et al.  Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  T. Kündig,et al.  Epicutaneous allergen administration: is this the future of allergen‐specific immunotherapy? , 2011, Allergy.

[15]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[16]  R. Dummer,et al.  Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients , 2010, Journal of immunotherapy.

[17]  Sudhir Gupta,et al.  TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors , 2010, Journal of Clinical Immunology.

[18]  H. Riechelmann,et al.  Efficacy and Safety of a Glutaraldehyde-Modified House Dust Mite Extract in Allergic Rhinitis , 2010, American journal of rhinology & allergy.

[19]  M. Blaiss.  Allergic rhinitis: Direct and indirect costs. , 2010, Allergy and asthma proceedings.

[20]  J. Farrar,et al.  Cutting Edge: Type I IFN Reverses Human Th2 Commitment and Stability by Suppressing GATA3 , 2010, The Journal of Immunology.

[21]  J. Yewdell.  Designing CD8+ T cell vaccines: it's not rocket science (yet). , 2010, Current opinion in immunology.

[22]  Hyunjin Shin,et al.  TLR Cross-Talk Specifically Regulates Cytokine Production by B Cells from Chronic Inflammatory Disease Patients1 , 2009, The Journal of Immunology.

[23]  M. Bachmann,et al.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy , 2009, The Journal of experimental medicine.

[24]  J. M. Grant,et al.  Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells , 2009, PLoS pathogens.

[25]  T. Kündig,et al.  Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  A. Krieg,et al.  Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. , 2009, Advanced drug delivery reviews.

[27]  J. Rolland,et al.  Allergen-related approaches to immunotherapy. , 2009, Pharmacology & therapeutics.

[28]  B. Wüthrich,et al.  Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial , 2008, Proceedings of the National Academy of Sciences.

[29]  K. Blaser.  Immunologische Grundlagen der allergenspezifischen Immuntherapie , 2008, HNO.

[30]  W. Sterry,et al.  Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma , 2008, Journal of immunotherapy.

[31]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[32]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[33]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[34]  G. Weiner,et al.  CpG oligodeoxynucleotides as immunotherapy in cancer. , 2008, Update on cancer therapeutics.

[35]  S. Kippenberger,et al.  Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. , 2008, Current opinion in molecular therapeutics.

[36]  B. Lambrecht,et al.  GATA3-Driven Th2 Responses Inhibit TGF-β1–Induced FOXP3 Expression and the Formation of Regulatory T Cells , 2007, PLoS biology.

[37]  B. Bacon,et al.  Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus , 2007, Hepatology.

[38]  P. Kuna,et al.  Decreased markers of atopy in children with presumed early exposure to allergens, unhygienic conditions, and infections. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[39]  A. Krieg.  Antiinfective applications of toll-like receptor 9 agonists. , 2007, Proceedings of the American Thoracic Society.

[40]  J. Kline.  Eat dirt: CpG DNA and immunomodulation of asthma. , 2007, Proceedings of the American Thoracic Society.

[41]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[42]  B. Chackerian,et al.  Virus-like particles: flexible platforms for vaccine development , 2007, Expert review of vaccines.

[43]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[44]  R. Coffman,et al.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.

[45]  A. Krieg.  Development of TLR9 agonists for cancer therapy. , 2007, The Journal of clinical investigation.

[46]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[47]  M. Larché,et al.  Update on the current status of peptide immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[48]  R. Valenta,et al.  Recombinant allergens for immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[49]  M. Benson,et al.  Expression of Toll-like Receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis , 2007, Respiratory research.

[50]  M. Kapsenberg,et al.  Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. , 2007, The Journal of investigative dermatology.

[51]  A. Sheikh,et al.  Allergen injection immunotherapy for seasonal allergic rhinitis. , 2007, The Cochrane database of systematic reviews.

[52]  X. Qin,et al.  Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligand , 2007, The Journal of experimental medicine.

[53]  B. Wüthrich,et al.  Immunotherapeutic targeting of allergic disease. , 2006, Inflammation & allergy drug targets.

[54]  R. Coffman,et al.  Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.

[55]  C. Akdis,et al.  Mechanisms of allergen specific immunotherapy – T‐cell tolerance and more , 2006, Allergy.

[56]  T. Kündig,et al.  Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. , 2006, The Journal of allergy and clinical immunology.

[57]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[58]  H. Fiebig,et al.  Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. , 2006, Immunology and allergy clinics of North America.

[59]  Sai T Reddy,et al.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[60]  H. Malling,et al.  Side‐effects of allergen‐specific immunotherapy. A prospective multi‐centre study , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[61]  R. Coffman,et al.  Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction , 2005, The Journal of experimental medicine.

[62]  Cezmi A Akdis,et al.  T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. , 2005, The Journal of allergy and clinical immunology.

[63]  B. Baban,et al.  Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.

[64]  S. Plotkin,et al.  Vaccines: past, present and future , 2005, Nature Medicine.

[65]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[66]  D. Speiser,et al.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.

[67]  J. Friedberg,et al.  Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. , 2005, Blood.

[68]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[69]  S. Durham,et al.  Prevalence and rate of diagnosis of allergic rhinitis in Europe , 2004, European Respiratory Journal.

[70]  C. Cooper,et al.  CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.

[71]  Y. Li,et al.  Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. , 2004, Vaccine.

[72]  H. Matsue,et al.  TLR3-, TLR7-, and TLR9-Mediated Production of Proinflammatory Cytokines and Chemokines from Murine Connective Tissue Type Skin-Derived Mast Cells but Not from Bone Marrow-Derived Mast Cells 1 , 2004, The Journal of Immunology.

[73]  C. L. Hardy,et al.  Blocking antibodies in allergen immunotherapy: the Yin and Yang , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[74]  S. Durham,et al.  Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity1 , 2004, The Journal of Immunology.

[75]  S. Durham,et al.  Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[76]  S. Halperin,et al.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.

[77]  C. Bode,et al.  CpG DNA as a vaccine adjuvant , 2003, Expert review of vaccines.

[78]  J. Bousquet,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) , 2003 .

[79]  G. Lipowsky,et al.  Regulation of IgG antibody responses by epitope density and CD21‐mediated costimulation , 2002, European journal of immunology.

[80]  D. Nowak,et al.  Environmental exposure to endotoxin and its relation to asthma in school-age children. , 2002, The New England journal of medicine.

[81]  P. Eng,et al.  Long‐term efficacy of preseasonal grass pollen immunotherapy in children , 2002, Allergy.

[82]  M. Khan,et al.  Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[83]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[84]  Dennis Nowak,et al.  Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey , 2001, The Lancet.

[85]  N. York,et al.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study. , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[86]  M. Swartz,et al.  The physiology of the lymphatic system. , 2001, Advanced drug delivery reviews.

[87]  J. Castro‐Rodriguez,et al.  Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. , 2000, The New England journal of medicine.

[88]  W Chiu,et al.  Structures of virus and virus-like particles. , 2000, Current opinion in structural biology.

[89]  I. Frazer,et al.  HPV6b virus like particles are potent immunogens without adjuvant in man. , 2000, Vaccine.

[90]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[91]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[92]  D. P. Strachan,et al.  Hay fever, hygiene, and household size. , 1989, BMJ.

[93]  C. Schmidt‐Weber.  Anti-IL-4 as a new strategy in allergy. , 2012, Chemical immunology and allergy.

[94]  L. Capelle,et al.  Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. , 2006, Neuro-oncology.

[95]  R. Steinman,et al.  The innate functions of dendritic cells in peripheral lymphoid tissues. , 2005, Advances in experimental medicine and biology.